for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

CareDx Inc

CDNA.OQ

Latest Trade

39.51USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

35.66

 - 

96.75

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
39.51
Open
--
Volume
--
3M AVG Volume
16.76
Today's High
--
Today's Low
--
52 Week High
96.75
52 Week Low
35.66
Shares Out (MIL)
52.80
Market Cap (MIL)
2,002.79
Forward P/E
112.39
Dividend (Yield %)
--

Next Event

Q4 2021 CareDx Inc Earnings Release

Latest Developments

More

CareDx Reports Preliminary Revenue Results For Fourth Quarter And Full Year 2021

CareDx Reports Q3 Results, Increases Full-Year Revenue Guidance

Caredx Reports 77% Revenue Growth For Second Quarter Of 2021

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About CareDx Inc

CareDx, Inc. is a precision medicine company. The Company is focused on the discovery, development and commercialization of clinically differentiated diagnostic solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company’s commercially available testing services consist of AlloSure Kidney, which is a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients, AlloMap Heart, which is a gene expression solution for heart transplant patients, and AlloSure Heart, a dd-cf-DNA solution for heart transplant patients. Its suite of AlloSeq products include: AlloSeq Tx, AlloSeq cfDNA, AlloSeq HCT, TruSight HLA, Olerup SSP and QTYPE. It also provides transplant patient tracking software, Ottr software, as well as of transplant quality tracking and waitlist management solutions.

Industry

Healthcare Facilities

Contact Info

1 Tower Place, 9Th Floor

SOUTH SAN FRANCISCO, CA

94080

United States

+1.415.2872300

https://www.caredx.com/

Executive Leadership

Michael D. Goldberg

Independent Chairman of the Board

Reginald Seeto

President, Chief Executive Officer, Director

Ankur Dhingra

Chief Financial Officer

Sasha King

Chief Marketing Officer

Marcel Konrad

Vice President, Corporate Controller

Key Stats

1.71 mean rating - 7 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.1K

2019

0.1K

2020

0.2K

2021(E)

0.3K
EPS (USD)

2018

-0.150

2019

0.100

2020

0.230

2021(E)

0.345
Price To Earnings (TTM)
--
Price To Sales (TTM)
7.26
Price To Book (MRQ)
4.24
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-4.60
Return on Equity (TTM)
-3.93

Latest News

Latest News

BRIEF-New Kidney360 Publication Highlights Caredx’S Allosure Is Differentiated As The Dd-Cfdna Test Of Choice

* NEW KIDNEY360 PUBLICATION HIGHLIGHTS CAREDX’S ALLOSURE IS DIFFERENTIATED AS THE DD-CFDNA TEST OF CHOICE

BRIEF-Caredx Files Preliminary Prospectus Supplement Related To $100 Mln Common Stock Offering - SEC Filing

* CAREDX FILES PRELIMINARY PROSPECTUS SUPPLEMENT RELATED TO $100 MILLION COMMON STOCK OFFERING - SEC FILING Source : (https://bit.ly/37nRhjC) Further company coverage:

BRIEF-Caredx's Alloseq Tx 17 Awarded CE Mark Approval

* CAREDX'S ALLOSEQ TX 17 AWARDED CE MARK APPROVAL Source text for Eikon: Further company coverage:

BRIEF-Caredx And Veracyte Announce Partnership For Transplant Rejection Testing On Ncounter System

* CAREDX AND VERACYTE ANNOUNCE EXCLUSIVE PARTNERSHIP FOR TRANSPLANT REJECTION TESTING ON NCOUNTER SYSTEM

BRIEF-CareDx Says Withdrew Previously Issued Full Year 2020 Revenue Guidance

* CAREDX REPORTS PRELIMINARY FIRST QUARTER 2020 REVENUE AND PROVIDES BUSINESS UPDATE IN RESPONSE TO COVID-19 PANDEMIC

BRIEF-CareDx Posts Q4 Non-GAAP Earnings Per Share Of $0.04

* Q4 REVENUE $35.8 MILLION VERSUS REFINITIV IBES ESTIMATE OF $35.8 MILLION

BRIEF-Caredx's Patent Rights Upheld By Delaware Court

* CAREDX - COURT RECOMMENDED DENIAL OF NATERA INC.'S & EUROFINS VIRACOR INC.'S MOTIONS TO DISMISS CAREDX'S PATENT INFRINGEMENT COMPLAINTS AGAINST THEM

IN BRIEF: Judge won’t dismiss patent suit over Natera’s kidney transplant rejection test

A patent infringement lawsuit by Stanford University and licensee CareDx Inc against genetic testing company Natera Inc survived a motion to dismiss on Tuesday in U.S. District Court in Delaware.

CareDx adds false advertising claims to patent dispute with Natera

Medical diagnostics company CareDx Inc on Wednesday escalated a legal battle with rival Natera Inc over kidney transplant technology, adding false advertising claims in a new lawsuit to what began as a patent dispute.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up